EyePoint Pharmaceuticals (EYPT) Q4 2025 earnings summary

Executive summary

• Advanced pivotal Phase III trials for DURAVYU in wet AMD and DME, with first patients dosed in both DME studies and topline data for wet AMD expected in mid-2026 and DME in the second half of 2027.

• Maintained a strong cash position of $306 million at year-end 2025, supporting operations into Q4 2027 and positioning for transformative growth with multiple near-term inflection points.

• Appointed a new Chief Commercial Officer to lead DURAVYU launch strategy and readiness.

• Expanded commercial leadership and manufacturing capabilities, including operational Massachusetts facility, to support future product launch and regulatory submissions.

Financial highlights

• Ended 2025 with $306 million in cash and investments, bolstered by a $173 million follow-on financing in October.

• Q4 2025 net revenue was $0.6 million, down from $11.6 million in Q4 2024, mainly due to lower license and royalty revenue and prior deferred revenue recognition.

• Q4 2025 operating expenses rose to $71 million from $57 million year-over-year, driven by Phase III trial costs.

• Q4 2025 net loss was $68 million ($0.81/share), compared to $41 million ($0.64/share) in Q4 2024.

• Full-year 2025 net revenue was $31.4 million, down from $43.3 million in 2024; net loss was $232 million ($3.17/share) versus $131 million ($2.32/share) in 2024.

Outlook and guidance

• Cash and investments expected to fund operations into Q4 2027, covering key milestones and NDA preparation for wet AMD and DME programs.

• Top-line data for Phase III wet AMD program expected in mid-2026, with DME data anticipated in the second half of 2027.

• Focused on completing DME Phase III enrollment in H2 2026 and preparing for regulatory filings, assuming positive data.